Search Result
Results for "
IL6 monoclonal antibody
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
-
- HY-P99165
-
|
|
IGF-1R
TSH Receptor
|
Endocrinology
|
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
-
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
-
-
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
-
- HY-P990212
-
|
|
Interleukin Related
STAT
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
|
-
-
- HY-P99112
-
|
RG-6168; SA-237
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
-
-
- HY-P9916
-
|
Anti-Human IL6Rα, Human antibody
|
Interleukin Related
STAT
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis .
|
-
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
LDLR
|
Inflammation/Immunology
Endocrinology
|
|
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
|
-
-
- HY-P99754
-
|
BCD-085
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
-
- HY-P99210
-
-
-
- HY-P991400
-
|
|
TNF Receptor
Apoptosis
Interleukin Related
NF-κB
JNK
p38 MAPK
|
Inflammation/Immunology
|
|
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
|
-
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
-
- HY-P990937
-
|
PF-04236921; TOUR-006
|
Interleukin Related
|
Inflammation/Immunology
|
|
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
|
-
-
- HY-P99252
-
|
Anti-Human CD6 Recombinant antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
-
- HY-P990012
-
|
EBI-031
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
|
-
-
- HY-P99390
-
|
MCLA 117
|
CD3
Interleukin Related
IFNAR
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
|
-
-
- HY-P99012
-
|
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
|
-
-
- HY-P99287
-
|
B-E8; Anti-IL-6 MAB B-E8
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
|
-
-
- HY-P990001
-
|
|
Interleukin Related
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
|
-
-
- HY-P990198
-
|
|
Galectin
|
Inflammation/Immunology
|
|
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonal antibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry .
|
-
-
- HY-P990242
-
|
|
Galectin
TNF Receptor
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
|
-
-
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
-
- HY-P991658
-
|
ARGX-109; GB224; RYI-008
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
|
-
-
- HY-P991602
-
|
TZLS-501
|
Interleukin Related
|
Cancer
|
|
NI-1201 is a monoclonal antibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R .
|
-
-
- HY-P991601
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
|
-
-
- HY-P991288
-
-
-
- HY-P991286
-
-
-
- HY-P991287
-
-
-
- HY-P991370
-
|
|
STAT
|
Cancer
|
|
SBT-100 (His Tag) is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 (His Tag) inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 (His Tag) has tumor growth inhibitory effects on MDA-MB-231 .
|
-
-
- HY-P991426
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
|
-
-
- HY-P991310
-
|
LT3015; LT-3000
|
LPL Receptor
|
Neurological Disease
Cancer
|
|
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-P990252
-
|
|
Notch
Interleukin Related
NF-κB
VEGFR
FGFR
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .
|
-
-
- HY-P991519
-
-
-
- HY-P991600
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonal antibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
|
-
-
- HY-P992153
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Serrumab is a human monoclonal antibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion .
|
-
-
- HY-P992487
-
|
|
Claudin
Fc Receptor (FcR)
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
ZL-1211 is an anti-CLDN18.2 monoclonal antibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer .
|
-
-
- HY-P992045
-
|
|
Interleukin Related
CXCR
|
Inflammation/Immunology
|
|
HZD37-5 is a humanized monoclonal antibody specifically recognizing N78 loci of IL-17A. HZD37-5 binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and GM-GSF. HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant secretion. HZD37-5 can be used for the research of autoimmune diseases including psoriasis and psoriatic arthritis .
|
-
-
- HY-P992201
-
|
CL1-R2
|
MHC
Apoptosis
IFNAR
TNF Receptor
Interleukin Related
Akt
mTOR
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
(5)
-
- HY-P99165
-
|
|
IGF-1R
TSH Receptor
|
Endocrinology
|
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
-
(5)
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
MDM-2/p53
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
|
-
(5)
-
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
(5)
-
- HY-P990212
-
|
|
Interleukin Related
STAT
|
Infection
Inflammation/Immunology
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE) .
|
-
(5)
-
- HY-P99112
-
|
RG-6168; SA-237
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
-
(5)
-
- HY-P9916
-
|
Anti-Human IL6Rα, Human antibody
|
Interleukin Related
STAT
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis .
|
-
(5)
-
- HY-P99555
-
|
OPN-305
|
Toll-like Receptor (TLR)
MyD88
NOD-like Receptor (NLR)
Tau Protein
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
|
-
(5)
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
LDLR
|
Inflammation/Immunology
Endocrinology
|
|
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
|
-
(5)
-
- HY-P99754
-
|
BCD-085
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
(5)
-
- HY-P99210
-
-
(5)
-
- HY-P991400
-
|
|
TNF Receptor
Apoptosis
Interleukin Related
NF-κB
JNK
p38 MAPK
|
Inflammation/Immunology
|
|
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
|
-
(5)
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
(5)
-
- HY-P990937
-
|
PF-04236921; TOUR-006
|
Interleukin Related
|
Inflammation/Immunology
|
|
Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
|
-
(5)
-
- HY-P99252
-
|
Anti-Human CD6 Recombinant antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
(5)
-
- HY-P990012
-
|
EBI-031
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
|
-
(5)
-
- HY-P99390
-
|
MCLA 117
|
CD3
Interleukin Related
IFNAR
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
|
-
(5)
-
- HY-P99012
-
|
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
|
-
(5)
-
- HY-P99287
-
|
B-E8; Anti-IL-6 MAB B-E8
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
|
-
(5)
-
- HY-P990001
-
|
|
Interleukin Related
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
|
-
(5)
-
- HY-P990198
-
|
|
Galectin
|
Inflammation/Immunology
|
|
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived anti-mouse/human Mac-2/Galectin-3 IgG2a monoclonal antibody. Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) significantly inhibits IL-6 expression (inhibition rates 34.7% and 55.3%). Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is often used for immunoprecipitation, western blot, immunofluorescence, and flow cytometry .
|
-
(5)
-
- HY-P990242
-
|
|
Galectin
TNF Receptor
IFNAR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 + and CD8 + T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .
|
-
(5)
-
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
(5)
-
- HY-P991658
-
|
ARGX-109; GB224; RYI-008
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis .
|
-
(5)
-
- HY-P991602
-
|
TZLS-501
|
Interleukin Related
|
Cancer
|
|
NI-1201 is a monoclonal antibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R .
|
-
(5)
-
- HY-P991601
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
|
-
(5)
-
- HY-P991288
-
-
(5)
-
- HY-P991286
-
-
(5)
-
- HY-P991287
-
-
(5)
-
- HY-P991370
-
|
|
STAT
|
Cancer
|
|
SBT-100 (His Tag) is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 (His Tag) inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 (His Tag) has tumor growth inhibitory effects on MDA-MB-231 .
|
-
(5)
-
- HY-P991426
-
|
|
Transmembrane Glycoprotein
IFNAR
TNF Receptor
|
Cancer
|
|
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
|
-
(5)
-
- HY-P991310
-
|
LT3015; LT-3000
|
LPL Receptor
|
Neurological Disease
Cancer
|
|
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P991595
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P990252
-
|
|
Notch
Interleukin Related
NF-κB
VEGFR
FGFR
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma .
|
-
(5)
-
- HY-P991519
-
-
(5)
-
- HY-P991600
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonal antibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
|
-
(5)
-
- HY-P992153
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Serrumab is a human monoclonal antibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion .
|
-
(5)
-
- HY-P992487
-
|
|
Claudin
Fc Receptor (FcR)
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
ZL-1211 is an anti-CLDN18.2 monoclonal antibody. ZL-1211 exhibits enhanced binding affinity to CD16A. ZL-1211 induces ADCC-mediated cell lysis and triggers the production of IFNγ, TNFα and IL6. ZL-1211 promotes antibody-dependent cellular cytotoxicity. ZL-1211 exerts anti-tumor activity in a mouse xenograft model of gastric cancer. ZL-1211 can be used for the research of gastric cancer .
|
-
(5)
-
- HY-P992045
-
|
|
Interleukin Related
CXCR
|
Inflammation/Immunology
|
|
HZD37-5 is a humanized monoclonal antibody specifically recognizing N78 loci of IL-17A. HZD37-5 binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and GM-GSF. HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant secretion. HZD37-5 can be used for the research of autoimmune diseases including psoriasis and psoriatic arthritis .
|
-
(5)
-
- HY-P992201
-
|
CL1-R2
|
MHC
Apoptosis
IFNAR
TNF Receptor
Interleukin Related
Akt
mTOR
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma .
|
-
(5)
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
